Literature DB >> 1303858

Long-term results of systemic chemotherapy for ocular cicatricial pemphigoid.

C S Foster1, R Neumann, J Tauber.   

Abstract

Ocular cicatricial pemphigoid (OCP) is a chronic, progressive, blinding, autoimmune disease that scars mucous membranes. We studied the long-term outcome in 104 consecutive patients (average follow-up: 4 years) to determine whether complete remission could be achieved following a course of treatment with immunosuppressive drugs. We found that prolonged periods of remission off therapy are maintained in about one third of OCP patients. Follow-up must be continued for life as relapse occurs in approximately one third of cases. Those who relapsed regained disease control readily upon reinstitution of therapy and did not deteriorate to more advanced cicatrization. Sex, age, initial degree of inflammation and the incidence of extraocular involvement did not bear a prognostic significance. The mechanism which underlies the differing responses to therapy is not yet known.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1303858     DOI: 10.1007/bf00160769

Source DB:  PubMed          Journal:  Doc Ophthalmol        ISSN: 0012-4486            Impact factor:   2.379


  9 in total

Review 1.  Cicatricial pemphigoid and erythema multiforme.

Authors:  B J Mondino
Journal:  Ophthalmology       Date:  1990-07       Impact factor: 12.079

2.  Systemic chemotherapy for ocular cicatricial pemphigoid.

Authors:  J Tauber; M Sainz de la Maza; C S Foster
Journal:  Cornea       Date:  1991-05       Impact factor: 2.651

3.  Cicatricial pemphigoid.

Authors:  C S Foster
Journal:  Trans Am Ophthalmol Soc       Date:  1986

4.  Benign mucous membrane pemphigoid. Response to therapy with cyclophosphamide.

Authors:  H J Brody; D J Pirozzi
Journal:  Arch Dermatol       Date:  1977-11

5.  Azathioprine in the treatment of muco-cutaneous pemphigoid.

Authors:  V K Dave; C F Vickers
Journal:  Br J Dermatol       Date:  1974-02       Impact factor: 9.302

6.  Benign mucous membrane pemphigoid.

Authors:  K M Hardy; H O Perry; G C Pingree; T J Kirby
Journal:  Arch Dermatol       Date:  1971-11

7.  Treatment of cicatricial (benign mucous membrane) pemphigoid with dapsone.

Authors:  R S Rogers; J R Seehafer; H O Perry
Journal:  J Am Acad Dermatol       Date:  1982-02       Impact factor: 11.527

8.  Immunosuppressive therapy for progressive ocular cicatricial pemphigoid.

Authors:  C S Foster; L A Wilson; M B Ekins
Journal:  Ophthalmology       Date:  1982-04       Impact factor: 12.079

9.  Immunosuppressive therapy in ocular cicatricial pemphigoid.

Authors:  B J Mondino; S I Brown
Journal:  Am J Ophthalmol       Date:  1983-10       Impact factor: 5.258

  9 in total
  5 in total

Review 1.  The 2016 Bowman Lecture Conjunctival curses: scarring conjunctivitis 30 years on.

Authors:  J K Dart
Journal:  Eye (Lond)       Date:  2017-01-20       Impact factor: 3.775

Review 2.  Mucous membrane pemphigoid.

Authors:  Hong-Hui Xu; Victoria P Werth; Ernesta Parisi; Thomas P Sollecito
Journal:  Dent Clin North Am       Date:  2013-08-15

Review 3.  [Mucous membrane pemphigoid with ocular involvement. Part II: therapy].

Authors:  T Meyer-ter-Vehn; E Schmidt; D Zillikens; G Geerling
Journal:  Ophthalmologe       Date:  2008-04       Impact factor: 1.059

Review 4.  Ocular Mucous Membrane Pemphigoid: Current State of Pathophysiology, Diagnostics and Treatment.

Authors:  Panagiotis Georgoudis; Francesco Sabatino; Nora Szentmary; Sotiria Palioura; Eszter Fodor; Samer Hamada; Hendrik P N Scholl; Zisis Gatzioufas
Journal:  Ophthalmol Ther       Date:  2019-01-29

5.  European guidelines (S3) on diagnosis and management of mucous membrane pemphigoid, initiated by the European Academy of Dermatology and Venereology - Part I.

Authors:  H Rashid; A Lamberts; L Borradori; S Alberti-Violetti; R J Barry; M Caproni; B Carey; M Carrozzo; F Caux; G Cianchini; A Corrà; G F H Diercks; F G Dikkers; G Di Zenzo; C Feliciani; G Geerling; G Genovese; M Hertl; P Joly; A V Marzano; J M Meijer; V Mercadante; D F Murrell; M Ormond; H H Pas; A Patsatsi; C Prost; S Rauz; B D van Rhijn; M Roth; E Schmidt; J Setterfield; G Zambruno; D Zillikens; B Horváth
Journal:  J Eur Acad Dermatol Venereol       Date:  2021-07-10       Impact factor: 6.166

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.